[1]沈　莲,宋海涛,孟令新.放射治疗联合安罗替尼治疗非小细胞肺癌伴脑转移瘤疗效观察[J].新乡医学院学报,2021,38(11):1062-1066.[doi:10.7683/xxyxyxb.2021.11.012]
　SHEN Lian,SONG Haitao,MENG Lingxin.Clinical efficacy of radiotherapy combined with anlotinib in the treatment of non-small cell lung cancer with brain metastases[J].Journal of Xinxiang Medical University,2021,38(11):1062-1066.[doi:10.7683/xxyxyxb.2021.11.012]
点击复制

放射治疗联合安罗替尼治疗非小细胞肺癌伴脑转移瘤疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年11
页码:
1062-1066
栏目:
临床研究
出版日期:
2021-11-05

文章信息/Info

Title:
Clinical efficacy of radiotherapy combined with anlotinib in the treatment of non-small cell lung cancer with brain metastases
作者:
沈　莲1; 2; 宋海涛2; 孟令新2
（1.日照市第二人民医院肿瘤科,山东　日照　276800；2.日照市人民医院肿瘤科，山东　日照　276826）
Author(s):
SHEN Lian1; 2; SONG Haitao2; MENG Lingxin2
（1.Department of Oncology,the Second People′s Hospital of Rizhao,Rizhao 276800,Shandong Province,China；2.Department of Oncology，the People′s Hospital of Rizhao，Rizhao 276826，Shandong Province，China）
关键词:
安罗替尼; 非小细胞肺癌; 脑转移; 放射治疗
Keywords:
anlotinib; non-small cell lung cancer; brain metastases; radiotherapy
分类号:
R734.2
DOI:
10.7683/xxyxyxb.2021.11.012
文献标志码:
A
摘要:
目的　探讨放射治疗联合安罗替尼治疗非小细胞肺癌(NSCLC)伴脑转移瘤的疗效及安全性，为晚期肺癌的临床治疗提供参考依据。方法　选择2017年5月至2020年1月日照市人民医院收治的 NSCLC 伴脑转移瘤患者48例为研究对象,根据治疗方法将患者分为观察组（n=20）和对照组（n=28）。2组患者的脑转移瘤均给予放射治疗，在此基础上，观察组患者同期给予安罗替尼12 mg，口服，每日1次；对照组患者同期给予培美曲塞联合卡铂化学治疗方案，2组均以21 d为1个疗程，至少完成2个疗程的治疗。研究的主要终点指标为患者的无进展生存期(PFS)和总生存期(OS)。每治疗2个疗程进行1次影像学评估，比较2组患者的疗效和不良反应发生率。结果　观察组患者完全缓解（CR）3例，部分缓解（PR）4例，疾病稳定（SD）10例，疾病进展（PD）3例，客观缓解率（ORR）为35.00%（7/20），疾病控制率（DCR）为85.00%（17/20）；对照组患者CR 2例，PR 4例，SD 9例，PD 13例，ORR为21.43%（6/28），DCR为53.57%（15/28）。观察组患者的DCR显著高于对照组（χ2=3.868，P=0.049）；2组患者的ORR比较差异无统计学意义（χ2=0.509，P=0.475）。观察组和对照组患者的中位PFS分别为3.7、2.3个月，中位OS分别为5.5、3.8个月；观察组患者的中位PFS、OS均显著长于对照组（P=0.036、0.014）。对照组和观察组患者的不良反应发生率分别为 25.00%（7/28）、60.00%（12/20），对照组患者不良反应发生率显著低于观察组（χ2=5.976，P=0.015）。结论　放射治疗联合安罗替尼治疗晚期 NSCLC伴脑转移患者的近期疗效及远期生存疗效优于放射治疗联合卡铂治疗方案，且患者总体耐受较好。
Abstract:
Objective　To investigate the efficacy and safety of radiotherapy combined with anrotinib in the treatment of non-small cell lung cancer (NSCLC) patients with brain metastasis,and to provide reference for the clinical treatment of advanced lung cancer.Methods　A total of 48 NSCLC patients with brain metastasis admitted to the People′s Hospital of Rizhao from May 2017 to January 2020 were selected as the study subjects.The patients were divided into observation group (n=20) and control group (n=28) according to the treatment methods.All patients received radiation treatment for their brain metastases.Based on this,the patients in the observation group were given anlotinib 12 mg orally,once a daythe patients in the control group were treated with pemetrexed combined with carboplatin chemotherapy.All patients were completed at least two courses of treatment with 21 days as a course of treatment.The primary endpoint indexes were progression-free survival (PFS) and overall survival (OS).Imaging assessments was performed every two courses of treatment,the efficacy and the incidence of adverse reaction of patients were compared between the two groups.Results　In the observation group,there were 3 cases of complete response (CR),4 cases of partial response (PR),10 cases of stable disease (SD),and 3 cases of progressive disease (PD)the objective response rate (ORR) and disease control rate (DCR) were 35.00% (7/20) and 85.00% (17/20),respectively.In the control group,there were 2 cases of CR,4 cases of PR,9 cases of SD,and 13 cases of PDthe ORR and DCR were 21.4% (6/28) and 53.57% (15/28),respectively.The DCR of patients in the observation group was significantly higher than that in the control group(χ2=3.868,P=0.049)there was no significant difference in the ORR of patients between the two groups (χ2=0.509,P=0.475).The median PFS of patients in the observation group and control group was 3.7 months and 2.3 months,respectively；the median OS of patients in the observation group and control group was 5.5 months and 3.8 months，respectively.The median PFS and OS of patients in the observation group were significantly longer than those in the control group (P=0.036,0.014).The incidence of adverse reactions of patients in the observation group and control group was 60.00% (12/20) and 25.00% (7/28),respectivelythe incidence of adverse reactions of patients in the observation group was significantly higher than that in the control group (χ2=5.976,P=0.015).Conclusion　Radiotherapy combined with androtinib for NSCLC patients with brain metastases is better than radiotherapy combined with carboplatin in the short-term efficacy and long-term survival efficacy (PFS and OS),and the adverse reactions are controllable.

参考文献/References:

［1］　BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［2］　郑荣寿,孙可欣,张思维,等.2015 年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志,2019,41(1):19-28.
［3］　SYED Y Y.Anlotinib:first global approval［J］.Drugs,2018,78(10):1057-1062.
［4］　CHEN W,SUN K,ZHENG R,et al.Cancer incidence and mortality in China,2014［J］.Chin J Cancer Res,2018,30(1):1-12.
［5］　张晓春.2019肺癌精准治疗的前沿与展望［J］.医学研究生学报,2019,32(10):1009-1013.
［6］　JIANG S,LIANG H,LIU Z,et al.The impact of anlotinib on brain metastases of non-small cell lung cancer:post hoc analysis of a phase Ⅲ randomized control trial (ALTER0303)［J］.Oncologist,2020,25(5):e870-e874.
［7］　BROWN P D,JAECKLE K,BALLMAN K V,et al.Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases:a randomized clinical trial［J］.JAMA,2016,316(4):401-409.
［8］　PALMA D A,OLSON R,HARROW S,et al.Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET):a randomised,phase 2,open-label trial［J］.Lancet,2019,393(10185):2051-2058.
［9］　GOMEZ D R,TANG C,ZHANG J,et al.Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small cell lung cancer:long-term results of a mul-tiinstitutional,phase Ⅱ,randomized study［J］.J Clin Oncol,2019,37(18):1558-1565.
［10］　王聪,张国荣.脑转移瘤放射治疗后认知功能障碍机制及可能的防治策略［J］.中华放射医学与防护杂志,2016,36(10):797-800.
［11］　BALDUCCI M,AUTORINO R,CHIESA S,et al.Radiosurgery or fractiona-ted stereotactic radiotherapy plus whole-brain radioherapy in brain oligometastases:a long-term analysis［J］.Anticancer Res,2015,35(5):3055-3059.
［12］　杨旭,许光,雷振,等.RECIST1.1与WHO、RECIST1.0标准评价周边型肺癌疗效比较［J］.中国医学影像学杂志,2012,20(5):355-358,362.
［13］　石远凯,孙燕,于金明,等.中国肺癌脑转移诊治专家共识(2017版)［J］.中国肺癌杂志,2017,20(1):1-12
［14］　刘勇,张艳莉,刘岩.培美曲塞联合顺铂治疗晚期非小细胞肺癌疗效观察［J］.新乡医学院学报,2015,32(9):874-876.
［15］　THERASSE P,ARBUCK S G,EISENHAUER E A,et al.New guidelines to evaluate the response to treatment in solid tumors［J］.J Natl Cancer Inst,2000,92(3):205-216.
［16］　GOMEZ D R,BLUMENSCHEIN G R,LEE J J,et al.Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small cell lung cancer without progression after first-line systemic therapy:a multicentre,randomised,controlled,phase 2 study［J］.Lancet Oncol,2016,17(12):1672-1682.
［17］　李俊,陈飞.放射治疗与分子靶向药物在脑转移瘤治疗中的联合应用效果分析［J］.实用癌症杂志,2017,32(1):150-152.
［18］　姜力豪,欧阳举.Ⅳ期非小细胞肺癌综合治疗中放射治疗剂量和靶向维持治疗对预后的影响［J］.临床内科杂志,2019,36(10):697-699.
［19］　张亚娟,常德,张健鹏.肺癌化疗中铂类耐药的研究进展［J］.中国医学科学院学报,2017,39(1):150-155.
［20］　XIE C,WAN X,QUAN H,et al.Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.［J］.Cancer Science,2018,109(4):1207-1219.
［21］　HAN B,LI K,ZHAO Y，et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer：a multicentre，randomised phase Ⅱ trial （ALTER0302）［J］.Br J Cancer,2018,118(5):654-661.
［22］　金振兴,杜秀平.盐酸安罗替尼治疗晚期非小细胞肺癌的临床观察［J］.临床与病理杂志,2020,40(4):905-912.
［23］　孙新苑,何超然,娄安琦,等.安罗替尼三线治疗晚期肺癌的临床疗效及安全性分析［J］.临床药物治疗杂志,2020,18(4):54-57.
［24］　罗详冲,李高峰.安罗替尼治疗肺癌的临床研究进展［J］.中国肿瘤生物治疗杂志,2019,26(6):710-714.
［25］　姬颖华,杨晓煜,王瑾，等.安罗替尼联合伊立替康方案二线治疗晚期复发难治性小细胞肺癌的临床疗效观察［J］.新乡医学院学报,2021,38(4):28-31.
［26］　刘艺婧,卢凯华.安罗替尼治疗肺癌的临床研究进展［J］.现代肿瘤医学,2021,29(16):2936-2939.
［27］　HAN B，LI K，WANG Q，et al.Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced nonsmall cell lung cancer：the ALTER0303 phase 3 randomized clinical trial［J］.JAMA Oncol,2018,4(110):1569-1575.
［28］　沈娟,陈雪琴,马胜林.安罗替尼抗肿瘤作用研究进展［J］.浙江医学,2019,41(23):2556-2560.
［29］　黄行志,蔡凡,刘高,等.安罗替尼联合放疗治疗非小细胞肺癌伴脑转移的临床分析［J］.基层医学论坛,2020,24(1):5-7.
［30］　黄艾弥,王韡旻,钱洁,等.安罗替尼在晚期非小细胞肺癌中的近期疗效及安全性分析［J］.肿瘤药学,2019,9(5):793-797,808.
［31］　HAN B,KAI L,WANG Q,et al.Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303):a randomised,double-blind,placebo-controlled phase 3 study［J］.Lancet Oncology,2017,18:S3.
［32］　CHENG Y,WANG Q,LI K,et al.Anlotinib as third -line or further -line treatment in relapsed SCLC：a multicentre，randomized,double-blind phase 2 trial［J］.J Thorac Oncol,2018,13(10):351-352.

相似文献/References:

[1]张开普.介入治疗局部晚期非小细胞肺癌42例[J].新乡医学院学报,2002,19(05):421.
[2]牛红蕊,袁 亮,吴随群.羟基喜树碱联合顺铂和足叶乙甙治疗中晚期非小细胞肺癌39例[J].新乡医学院学报,2002,19(05):419.
[3]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌l7例[J].新乡医学院学报,2003,20(02):126.
[4]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌17 例[J].新乡医学院学报,2003,20(02):126.
[5]张海君,闫卫东,邝先奎.目的从伦理学的角度来思考基因歧视产生的原因和所引起的危害，并寻求对策。方法查阅并分析近1O年的文献。结果导致基因歧视产生的理论观点是不正确的，这种现象对人类有极大的危害，人们可以通过对隐私权的保护来避免或减轻它对人类的伤害。结论 基因歧视是不公正也是不[J].新乡医学院学报,2003,20(06):428.
[6]杨廷桐,李秀杰,武俊芳,等.端粒酶反转录酶活化与p53金属蛋白酶-9表达对非小细胞肺癌发生的影响[J].新乡医学院学报,2007,24(05):000.
[7]杨廷桐,武俊芳,李秀杰,等.非小细胞肺癌中p14ARF和mtp53蛋白表达与临床病理参数的关系[J].新乡医学院学报,2008,25(04):336.
[8]姬明丽,千智斌,徐自超.p53蛋白与非小细胞肺癌多药耐药性的关系[J].新乡医学院学报,2008,25(01):013.
[9]孙秀威,陈玉玲,黄鹏.非小细胞肺癌中核糖核苷酸还原酶亚单位M1 表达及其与吉西他滨化学治疗敏感性相关研究[J].新乡医学院学报,2011,28(02):157.
[10]郑翠侠,韩兵,周翔,等.非小细胞肺癌中表皮生长因子受体基因突变的筛查[J].新乡医学院学报,2011,28(02):190.

更新日期/Last Update: 2021-11-05